Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for …

5 days ago · Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function.

Nov 20, 2025 · News surrounding Illumina’s ongoing antitrust legal battles and recent strategic shifts, such as updates on the planned divestiture of GRAIL, have kept investors on edge. These major …

We are Illumina We are a global genomics and human health leader innovating the future of precision health. We develop DNA sequencing and array-based life sciences technologies to enable …

Illumina (ILMN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

2 days ago · NEW YORK – Illumina has long been content to supply as many sequencing reagents as the pharmaceutical industry could handle, but now the firm is willing to offer a more refined product: …

1 day ago · Zacks Research raised shares of Illumina from a "hold" rating to a "strong-buy" rating in a research note on Tuesday.

Illumina offers a broad range of sequencing and microarray products for diverse genomic analysis applications.

Dec 18, 2023 · Illumina’s decision to unwind its acquisition of Grail ensures the market for cancer detection tests remains competitive and delivers a choice of high-quality tests for patients and …